Strategic CDMO List Labs is an experienced CDMO specializing in live biotherapeutic products and bacterial-derived therapeutics, offering end-to-end development, manufacturing, and analytical services. This positions them as a potential partner for companies seeking scalable, cGMP-compliant production for preclinical through clinical stages.

LBP Expertise With over 45 years in handling aerobes, anaerobes, and spore formers, List Labs can support clients pursuing live biotherapeutic products, including process development, scale-up, aseptic filling, encapsulation, and QC testing—key capabilities for customers developing microbiome-based therapies.

Regulatory Ready Facility and capabilities span cGMP manufacturing for clinical trials and future commercial launch, signaling readiness to partner with biotech companies aiming to accelerate regulatory approvals and scale commercialization.

Toxin and Lipopolysaccharide Production In addition to LBPs, List Labs produces a range of bacterial toxins and LPS for research use, offering cross-sell opportunities to laboratories and biotech firms requiring specialized reagents and validated analytical materials.

Global Partnerships Past collaborations with Genome & Company and BetterLife Pharma demonstrate a track record of strategic partnerships and potential for co-development opportunities, suggesting List Labs is open to collaborative models with growth-focused biotech players.